Management of Immune Thrombocytopenia (ITP)

Primary Treatment Goal

The American Society of Hematology recommends that the fundamental treatment goal for ITP is achieving a platelet count that prevents major bleeding (≥50 × 10⁹/L), rather than normalizing the platelet count 1, 2
Treatment should only be initiated when the degree of thrombocytopenia and clinical condition increase the risk for bleeding, not simply based on platelet numbers alone 1, 2

The American College of Physicians recommends longer courses of corticosteroids as first-line treatment for ITP 1
Prednisone is the standard initial therapy at 0.5-2 mg/kg/day until platelet count increases to 30-50 × 10⁹/L, which may require several days to several weeks 3, 4
Prednisone should be rapidly tapered and stopped in responders, and especially in non-responders after 4 weeks to avoid corticosteroid-related complications 3, 4
Dexamethasone shows high initial response rates (86-90%) with sustained responses in 50-74% of patients when given as 40 mg/day for 4 days, either as a single cycle or up to 4 cycles given every 14 days 3, 4

For patients with uncontrolled bleeding or active CNS, GI, or genitourinary bleeding, the American Society of Hematology recommends combining prednisone and IVIg 2, 5
High-dose methylprednisolone may also be useful in emergency settings 2, 5
Platelet transfusion at larger-than-usual doses, possibly in combination with IVIg, should be considered in life-threatening situations 2, 5, 4

The American Society of Hematology recommends that second-line therapy should be considered for patients who fail initial corticosteroid therapy (relapse or unresponsive) or who cannot tolerate corticosteroid side effects 1
Splenectomy is typically deferred for at least 6 months to allow for potential spontaneous remission 2, 6, 7
Splenectomy remains the only treatment providing sustained remission off all treatments at 1 year and beyond in a high proportion of patients (approximately two-thirds) 1
Response rates to splenectomy: 80% of patients respond initially, with approximately two-thirds achieving lasting remission over 5-10 years 2, 5

The American College of Physicians recommends azathioprine as an immunosuppressive agent for ITP, with a dose of 1-2 mg/kg/day (maximum 150 mg/day) and a response rate of up to 45-67% of patients 2, 5, 6
Cyclosporin A is also recommended, with a dose of 5 mg/kg/day for 6 days, then 2.5-3 mg/kg/day (titrate to blood levels 100-200 ng/mL) and a response rate of 50-80% in small series, with 42% complete response 2, 5, 6
Mycophenolate mofetil is recommended, with a dose of 1000 mg twice daily for at least 3-4 weeks and a response rate of up to 75% of patients, with complete response in up to 45% 2, 5
Danazol is recommended, with a dose of 200 mg 2-4 times daily and a response rate of 40-67% complete or partial response 2, 5, 6, 7

The American Society of Hematology recommends weekly CBC with platelet counts during dose adjustment phase, monthly CBC monitoring after stable dose achieved, and weekly CBC for at least 2 weeks after discontinuation 1

The American College of Physicians recommends avoiding prolonged corticosteroid use, as detrimental effects often outweigh benefits with extended therapy 3
The American Society of Hematology recommends not using plasmapheresis, as there is no evidence of efficacy in chronic ITP 2, 7
Vaccination before splenectomy is essential to prevent overwhelming post-splenectomy infection 2

The American Society of Hematology recommends thrombopoietin receptor agonists (TPO-RAs) as the initial second-line therapy for refractory ITP, with overall platelet response rates of 88% in non-splenectomized patients and 79% in splenectomized patients 8
Romiplostim dosing is 1-10 µg/kg subcutaneous weekly injection, with sustained responses documented for up to 4 years with continuous administration 8
Eltrombopag dosing is 25-75 mg oral daily dose, with up to 30% of patients achieving long-term remission after tapering and discontinuation 8
Cyclosporin A 2.5-3 mg/kg/day has response rates of 50-80% with 42% complete response 8
Cyclophosphamide has response rates of 24-85% but carries a risk of acute myeloid leukemia 8
Dapsone 75-100 mg/day has response rates of up to 50% within 3 weeks, but requires screening for G6PD deficiency before starting 8

Rituximab is an alternative second-line option with initial response rates of 60% (40% complete response), and can be dosed at 100 mg or 375 mg/m² weekly for 4 weeks 9